GB2378383A - Nasal delivery of pharmaceutical compositions in powder form - Google Patents

Nasal delivery of pharmaceutical compositions in powder form Download PDF

Info

Publication number
GB2378383A
GB2378383A GB0113725A GB0113725A GB2378383A GB 2378383 A GB2378383 A GB 2378383A GB 0113725 A GB0113725 A GB 0113725A GB 0113725 A GB0113725 A GB 0113725A GB 2378383 A GB2378383 A GB 2378383A
Authority
GB
United Kingdom
Prior art keywords
delivery
nasal
pharmaceutical compositions
powder form
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0113725A
Other versions
GB0113725D0 (en
Inventor
Gursharan Moonga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB0113725A priority Critical patent/GB2378383A/en
Publication of GB0113725D0 publication Critical patent/GB0113725D0/en
Publication of GB2378383A publication Critical patent/GB2378383A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Abstract

The invention relates to methods of preparation of vaccines and pharmaceutical compositions for Nasal delivery. The nasal method of delivery of medicaments comprises new ways of treatment of individuals. The objective of the invention is to develop needle free drug delivery systems to facilitate faster delivery to the target in lower dosage. The introduction of the medicament in powder form in the nose by relative ease is attractive method in terms of patient compliance the other aspect of the invention relates to the Nasal delivery of pharmaceutical compositions of neurologic agents by means of olfactory neutral pathways. Theses agents included naturally occurring nerve growth promoting factors including phosphotidyl serine, insulin and insulin like growth factors.

Description

<Desc/Clms Page number 1>
Nasal Delivery of pharmaceutical compositions including vaccines and
biotechnological products.
Patent Application Number: By Dr Gursharan Moonga of BntHealth Drug Technologies, Business & Technology Centre, Bessemer Drive, Stevenage, Herts. SG 1 2DX England Description: The invention relates to methods of preparation of pharmaceutical and vaccines compositions for Nasal delivery. The nasal method of delivery of medicaments comprises new ways of treatment of individuals. The objective of the invention is to develop needle free drug delivery systems to facilitate faster delivery to the target in lower dosage.
The introduction of the medicament in powder form in the nose by relative ease is attractive method in terms of patient compliance the other aspect of the invention relates to the Nasal delivery of pharmaceutical compositions of neurologic agents by means of olfactory neutral pathways. Theses agents included naturally occurring nerve growth promoting factors including phosphotidyl serine, insulin and insulin like growth factors.
Background to the Invention: There are three main reasons for delivery of medicaments via the nose; a) Convenience b) Topical effect on the epithelium lining c) Systemic effect-superficial vessels can facilitate rapid absorption directly into the blood stream.
The nasal cavity area for drug absorption measuring approx 160cm2 and the turbulent airflow through the nose encourages inertial impaction of suspended particles into blanket of mucous covering highly vascularised nasal mucousa. The rapid passage of drugs across the nasal epithelium and into blood stream is the major advantage of nasal route of delivery, making the nose an ideal alternative to inject able route for some acute treatments as well as maintenance therapies currently delivered by injection. The delivery of medicaments and vaccines or peptides by Nasal route is promising as these areas have less enzymatic activity which might destroy polypeptides The problems have been encountered I the past for nasal delivery of macromolecules as only small portion of the drug could be absorbed. The other barrier of nasal bioavailability included mucocilliary clearance of the drug to the back of throat. The administration of peptides with aqueous nasal sprays has also proved problematic to include low bioavailability, local irritation of nasal mucosa.
The invention relates to the medicaments in a carrier system in powder form (in preservative free form to avoid irritation) manufactured using spray method of the active medicament on a carrier dextrin powder or locust bean powder, or Soya powder or milk powder which is inhaled by a device and active medicament comes in direct contact with mucosa and contributes to higher absorption These biotechnological products are more stable in dry solid state. It has been demonstrated by Scientists that a powder formulation remains longer on the nasal mucosa than a liquid formulation and particle size in nasal formulation is less critical. The dry powder bi-dose system consists of two profiled blisters that ensure optimum protection against vapor transmission, oxygen and light. The aerodynamic feature combined with easy actuation mode facilitates accurate and constant dosing in terms of expelled amount and inhalation forces.
<Desc/Clms Page number 2>
Delivers evenly over wider surface of nasal mucosa CLAIMS; 1. The inventor claims the delivery of neurologic agents for treatments of disorders such as Alzheimer's disease, Parkinson's disease, Aids, Schizophrenia, affective disorders such as depression, mania, anxietuy, addiction of substances such as opium etc, brain changes associated with age, pain due to head injuries, nerve damage from cardiovascular disorders such as stroke 2. The inventor claims of delivery of vaccines (in particular influenza, vaccines for infectious diseases and diabetes) and peptides (in particular insulin and calcitonin) and new class of biotechnological products.
3. The neurologic agent administered in powder form with the active sprayed or impregnated on carrier. The carrier examined included dextrin, locust bean powder, Soya powder or milk powder.
4. The inventor claims delivery of analgesics including Morphine and new class of
peptides/biotechnology products in spray powder form.
5. The inventor claims pharmaceutical composition of Seratonin (in spray powder form) for nasal delivery for treatment of depression.
6. The inventor claims pharmaceutical composition of Phosphotidyl serine for nasal delivery for enhancement of memory in pharmaceutical composition in spray powder form.
7. The inventor claims the active medicament spray method on carrier's dextrin, lipophilic compounds, chitosan, locust bean powder, Fenugreek powder, Soya flour, spray dried milk etc.
8. The pharmaceutical compositions/or vaccines in powder form sprayed on dextrin, locust bean powder, milk powder or Soya powder etc. for Nasal delivery 9. The inventor claims Nasal Delivery Device comprised of Shaped Nasal Canal (SNC) with inner tube fitting into the capsule containing powder (as shown in Fig 1) in single dose. A new capsule pre-filled with powder dosage can be used for each dose.
The dry powder bi-dose system made of two profiled blisters ensure optimum protection against vapor transmission, oxygen and light. The aerodynamic feature combined with easy actuation mode facilitates accurate and constant dosing in terms of expelled amount and inhalation forces. The system delivers evenly over wider surface of nasal mucosa.
**WARNING** end of DESC field may overlap start of CLMS **.

Claims (1)

  1. The invention offers innovate delivery of pharmaceutical compositions by Nasal route.
    **WARNING** end of CLMS field may overlap start of DESC **.
GB0113725A 2001-06-06 2001-06-06 Nasal delivery of pharmaceutical compositions in powder form Withdrawn GB2378383A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0113725A GB2378383A (en) 2001-06-06 2001-06-06 Nasal delivery of pharmaceutical compositions in powder form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0113725A GB2378383A (en) 2001-06-06 2001-06-06 Nasal delivery of pharmaceutical compositions in powder form

Publications (2)

Publication Number Publication Date
GB0113725D0 GB0113725D0 (en) 2001-07-25
GB2378383A true GB2378383A (en) 2003-02-12

Family

ID=9915997

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0113725A Withdrawn GB2378383A (en) 2001-06-06 2001-06-06 Nasal delivery of pharmaceutical compositions in powder form

Country Status (1)

Country Link
GB (1) GB2378383A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2397016A (en) * 2002-03-19 2004-07-14 Ionix Pharmaceuticals Ltd Intranasal analgesic composition comprising buprenorphine, & preferably chitosan or partially esterified pectin
GB2404431A (en) * 2003-06-24 2005-02-02 John Humphries Parkes Blast and fragmentation suppression device
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US8329196B2 (en) 2002-11-26 2012-12-11 Alk-Abello A/S Allergen dosage form
US8889176B2 (en) 2003-01-10 2014-11-18 Depomed, Inc. Method of managing or treating pain

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0571671A1 (en) * 1992-05-26 1993-12-01 The Procter & Gamble Company A Pharmaceutical composition in powder form
JPH07101817A (en) * 1993-08-10 1995-04-18 Mitsui Toatsu Chem Inc Curable composition for dental use
WO1995028158A1 (en) * 1994-04-13 1995-10-26 Janssen Pharmaceutica N.V. Intranasal antimigraine composition
WO1996003142A1 (en) * 1994-07-26 1996-02-08 Danbiosyst Uk Limited Drug delivery composition for the nasal administration of antiviral agents
WO1996005810A1 (en) * 1994-08-20 1996-02-29 Danbiosyst Uk Limited Drug delivery composition containing chitosan or derivative thereof having a defined z. potential
EP0943326A1 (en) * 1996-02-27 1999-09-22 Teijin Limited Powdery composition for nasal administration

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0571671A1 (en) * 1992-05-26 1993-12-01 The Procter & Gamble Company A Pharmaceutical composition in powder form
JPH07101817A (en) * 1993-08-10 1995-04-18 Mitsui Toatsu Chem Inc Curable composition for dental use
WO1995028158A1 (en) * 1994-04-13 1995-10-26 Janssen Pharmaceutica N.V. Intranasal antimigraine composition
WO1996003142A1 (en) * 1994-07-26 1996-02-08 Danbiosyst Uk Limited Drug delivery composition for the nasal administration of antiviral agents
WO1996005810A1 (en) * 1994-08-20 1996-02-29 Danbiosyst Uk Limited Drug delivery composition containing chitosan or derivative thereof having a defined z. potential
EP0943326A1 (en) * 1996-02-27 1999-09-22 Teijin Limited Powdery composition for nasal administration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WPI Abstract Accession No 1995-203751/27 & JP7101817A (DOT KK) *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB2397016B (en) * 2002-03-19 2004-10-27 Ionix Pharmaceuticals Ltd Intranasal analgesic composition containing buprenorphine
GB2397016A (en) * 2002-03-19 2004-07-14 Ionix Pharmaceuticals Ltd Intranasal analgesic composition comprising buprenorphine, & preferably chitosan or partially esterified pectin
US9408805B2 (en) 2002-11-26 2016-08-09 Alk-Abello A/S Allergen dosage form
US8329196B2 (en) 2002-11-26 2012-12-11 Alk-Abello A/S Allergen dosage form
US9415015B2 (en) 2002-11-26 2016-08-16 Alk-Abello A/S Allergen dosage form
US10080719B2 (en) 2002-11-26 2018-09-25 Alk-Abelló A/S Allergen dosage form
US10471008B2 (en) 2002-11-26 2019-11-12 Alk-Abelló A/S Allergen dosage form
US8889176B2 (en) 2003-01-10 2014-11-18 Depomed, Inc. Method of managing or treating pain
US9078814B2 (en) 2003-01-10 2015-07-14 Depomed, Inc. Intranasal spray device containing pharmaceutical composition
US9814705B2 (en) 2003-01-10 2017-11-14 Depomed, Inc. Intranasal spray device containing pharmaceutical composition
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
GB2404431B (en) * 2003-06-24 2008-03-12 John Humphries Parkes Blast and fragmentation suppression device
GB2404431A (en) * 2003-06-24 2005-02-02 John Humphries Parkes Blast and fragmentation suppression device

Also Published As

Publication number Publication date
GB0113725D0 (en) 2001-07-25

Similar Documents

Publication Publication Date Title
Kumar et al. Intranasal drug delivery: A non-invasive approach for the better delivery of neurotherapeutics
ES2243094T3 (en) ADMINISTRATION OF A MODULATED AEROSOLIZED ACTIVE AGENT WITH FLOW RESISTANCE.
Upadhyay et al. Intranasal drug delivery system-A glimpse to become maestro
KR101488025B1 (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
Alagusundaram et al. Nasal drug delivery system-an overview
EP1025859B1 (en) Powdery pernasal compositions
CA2464250C (en) Kit for the preparation of a pharmaceutical composition
Wermeling Intranasal delivery of antiepileptic medications for treatment of seizures
SK1502000A3 (en) Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols
BG65091B1 (en) Device for aerosolized active agent delivery
DE69832070D1 (en) A packaging unit for drug administration in the olfactory region
US11826465B2 (en) Nebulization formulations for delivery to lower respiratory tract
EP3590502A1 (en) Ambroxol dry powder for inhalation use with bronchial target
GB2378383A (en) Nasal delivery of pharmaceutical compositions in powder form
Gandhimathi et al. Breathable medicine: pulmonary mode of drug delivery
CN104667391A (en) Disposable intranasal brain targeted drug delivery device
Deshpande et al. Nasal drug delivery–a review
Ruby et al. Antiemetic drugs as a nasal drug delivery-a review
CN100515392C (en) Dry powder composition for improvement of effective position medical deposit
CN101401793B (en) Capsule type inhalation dust cloud agent
Dhakar Nasal drug delivery: success through integrated device development
Varsha et al. An overview study on nasal and intranasal delivery system of drug
Deshmukh et al. Formulation and Device Design to Increase Nose to Brain Drug Delivery System
Shrewsbury Trends and Advancements in Drug Delivery: What is the" perfect" method of drug delivery?
Martini et al. Nasal and pulmonary drug delivery systems

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)